摘要
目的探讨艾司西酞普兰与文拉法辛缓释胶囊治疗首诊重性抑郁障碍的疗效。方法将82例首诊的符合DSM-Ⅳ-TR的重性抑郁障碍患者,分为焦虑明显组和焦虑不明显组,将每组患者随机分为艾司西酞普兰组和文拉法辛组,分别采用艾司西酞普兰(来士普)剂量10～20mg/d、文拉法辛缓释胶囊(怡诺思)75～225mg/d治疗6周,疗效采用汉密尔顿抑郁量表17项(HAMD)减分率评定。结果艾司西酞普兰与文拉法辛缓释胶囊均能取得明显疗效;但对于伴有明显焦虑的患者(HAMA量表评分≥21分),文拉法辛治疗的疗效优于艾司西酞普兰;对于伴有焦虑不明显的患者,艾司西酞普兰的疗效较优于文拉法辛。结论对于伴有明显焦虑的患者,可以首选文拉法辛;对于焦虑不明显的首诊重性抑郁障碍患者,可首选艾思西酞普兰。
Objective To explore the effect of Escitalopram and Venlafaxine in the treatment of patients with initial diagnosis of major depressive disorder. Methods 82 patients with initial diagnosis of major depressive disorder were divided into anxiety group and non-anxiety group, and each group was divided into Escitalopram group and Venlafaxine group, with the treatment of Escitalopram （10 - 20 mg/d） and Venlafaxine sustained release capsules （75 - 225 mg/d） for 6 weeks respectively. The treatment effect was evaluated by decrease rate of Hamilton depression rating scale for depression （HAMD）. Results Both Venlafaxine and Escitalopram could achieve good clinical effect. For patients with anxiety （HAMA score ≥21）, the effect of Venlafaxine was superior to Escitalopram; but for patients without anxiety, the effect of Escitalopram was superior to Venlafaxine. Conclusions For patients with initial diagnosis of major depressive disorder complicated with anxiety, Venlafaxine is the first choice, but for patients without anxity, Escitalopram can be the first choice.
出处
《临床医学工程》
2013年第8期949-950,共2页
Clinical Medicine & Engineering
基金
广州市科技攻关项目(项目编号:2007Z3-E0611)
关键词
文拉法辛缓释胶囊
艾司西酞普兰片
焦虑
重性抑郁障碍
Venlafaxine sustained release capsule
Escitalopram tablet
Anxiety
Major depressive disorder
